ZURNAI (AUTOINJECTOR) (nalmefene hydrochloride) by Purdue Pharma is clinical pharmacology pharmacodynamics nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. First approved in 2024.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
ZURNAI is a nalmefene hydrochloride autoinjector designed to prevent or reverse opioid overdose effects including respiratory depression, sedation, and hypotension. It is an opioid antagonist with a longer duration of action than naloxone, administered via intramuscular or subcutaneous injection. The drug blocks over 80% of brain opioid receptors within 5 minutes and has no abuse potential or respiratory depression risk.
Recently approved autoinjector in the high-priority opioid overdose reversal market with significant public health tailwinds; early-stage commercial infrastructure build underway.
CLINICAL PHARMACOLOGY Pharmacodynamics Nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that nalmefene hydrochloride injection has a longer duration of action than naloxone…
Worked on ZURNAI (AUTOINJECTOR) at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moZURNAI represents a growth-stage launch opportunity in a high-profile public health category with significant reimbursement and adoption tailwinds. Career roles focus on market access, provider advocacy, and commercial scaling in an emerging competitive space.